BioXcel Therapeutics (BTAI) announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI: